Work Here?
Overview
Collate provides an AI-powered platform that automates the creation and management of documentation for drug development, medical devices, and diagnostics. It works by generating, organizing, and governing regulatory and quality documents while offering data discovery and governance tools to ensure high-quality data assets. It distinguishes itself by offering an end-to-end, life-sciences–focused solution that covers drug, device, and diagnostic workflows in one platform, reducing manual work and speeding up approvals. Its goal is to shorten development and regulatory timelines so researchers can focus on discovery and bring life-saving innovations to patients faster.
About Collate
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$125M
Headquarters
San Francisco, California
Founded
2025
Get referred to Collate
See people who can refer or advise you
Simplify's Take
What believers are saying
- Collate raised $95M Series C at ~$1B valuation in May 2025.
- It serves ~50 customers including major pharma and device makers.
- Documents once taking seven months now complete in one month or less.
What critics are saying
- AI hallucinations in GxP docs cause regulatory rejection within 6–12 months.
- FDA/EMA tightening audit rules adds costly human layers, eroding time savings.
- SAP and Salesforce outcompete Collate in enterprise data governance by 2027.
What makes Collate unique
- Collate is GxP-compliant AI-native software for life sciences documentation.
- It maintains human-in-the-loop oversight for audits and patient safety.
- The platform delivers 50–90% time savings with over 90% accuracy.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$125M
Above
Industry Average
Funded Over
2 Rounds
Y CombinatorIndustry standards
Benefits
Company Equity
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 28%1 year growth
↑ 28%2 year growth
↑ 0%Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.
Y Combinator's Surbhi Sarna has raised $30 million for Collate, a startup aiming to automate the tedious parts of running a life sciences business using AI.
Collate is Hiring for 13 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Collate
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$125M
Headquarters
San Francisco, California
Founded
2025
Collate is Hiring for 13 Jobs on Simplify!
Find jobs on Simplify and start your career today